Related Experiment Video
Updated: Nov 15, 2025

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
Hyponatraemia due to hypothyroidism: a rare side effect from pomalidomide
Anum Qureshi1, Ji Hyun Rhee2,3
1Internal Medicine, Greater Baltimore Medical Center, Towson, Maryland, USA.
Pomalidomide, used for multiple myeloma, can cause hypothyroidism. This case highlights the importance of monitoring thyroid function in patients receiving this drug to detect and manage this uncommon side effect.
Area of Science:
- Oncology
- Endocrinology
- Pharmacology
Background:
- Pomalidomide is an immunomodulatory drug frequently used for relapsed and refractory multiple myeloma (RRMM).
- Hypothyroidism is a recognized but uncommon adverse effect associated with pomalidomide therapy.
- Early identification and management of hypothyroidism are crucial for patient well-being and treatment adherence.
Related Concept Videos
Antihypertensive Drugs: Potassium-Sparing Diuretics
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...
Therapeutic Drug Monitoring: Affecting Factors
Heart Failure Drugs: Inotropic Agents
Antihypertensive Drugs: Thiazide-Class Diuretics
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...

